J&J hit by $572m verdict in Oklahoma opioid case

All eyes on Oklahoma as J&J awaits $17bn opioid case verdict

Novartis and Pear to develop substance use digital therapeut...

Novartis is set to develop and commercialise a range of digital therapeutics for patients with substance and opioid use disorders as it expands its work with Pear Therapeutics through a dea

Explore innovative approaches and novel targets in analgesic...

The opioid crisis has cost the economy $1 trillion since 2001 in the USA alone, and the prospect does not look like it will get better any time soon.

Troubled Mallinckrodt pays $1.2bn for Sucampo

Specialist pharma company Mallinckrodt announced on 26 December that it is to acquire Sucampo Pharmaceuticals for around $1.2 billion.

FDA encourages cheap abuse-deterrent painkillers

Regulator waiting for non-opioid alternatives to reach the market